Zobrazeno 1 - 10
of 218
pro vyhledávání: '"Francine R, Kaufman"'
Autor:
PARAMESH SHAMANNA, LISA SHAH, JAHANGIR MOHAMMED, MALUK MOHAMED, TERRENCE POON, MALA DHARMALINGAM, BANSHI SABOO, SURESH DAMODHARAN, ARUN VADAVI, MOHAMED THAJUDEEN, ASHOK KESHAVAMURTHY, FRANCINE R. KAUFMAN, SHASHANK R. JOSHI
Publikováno v:
Diabetes. 71
The study was designed to determine the effect of TPT vs. standard care (SC) on change in A1C and T2DM remission at 90 day intervals, in addition to multiple secondary endpoints. The TPT intervention uses the Whole-Body Digital Twin Platform, with AI
Autor:
ARNAUD E. JACQUIN, LUJAIN AL-KHAWI, PATRICIA SANCHEZ, SANAT MOHANTY, KATHERINE S. TWEDEN, FRANCINE R. KAUFMAN
Publikováno v:
Diabetes. 71
Background: The PROMISE Clinical Trial, conducted to assess safety and accuracy of a 180-day implantable CGM System, had 43 subjects implanted with a modified sensor containing sacrificial boronic acid (SBA) to reduce the degradation of the boronic a
Autor:
VENKATA N. VELVADAPU, JAMES M. MASCIOTTI, ANDREW D. DEHENNIS, PATRICIA SANCHEZ, KATHERINE S. TWEDEN, FRANCINE R. KAUFMAN, SORIN IOACARA
Publikováno v:
Diabetes. 71
Background: The Eversense CGM System sensor is implanted in the upper arm. It uses a fluorescent, boronic acid glucose-binding moiety to measure glucose. The glucose indicator is susceptible to oxidative de-boronation from reactive oxygen species (RO
Autor:
ARNAUD E. JACQUIN, LUJAIN AL-KHAWI, SAMANWOY GHOSH-DASTIDAR, KATHERINE S. TWEDEN, FRANCINE R. KAUFMAN
Publikováno v:
Diabetes. 71
Background: The PROMISE Clinical Study was conducted to determine the accuracy and safety of the next generation implantable CGM System. A subset of 43 subjects had a sensor implanted with modified chemistry referred to as sacrificial boronic acid (S
Autor:
Concetta Irace, Linda Tartaglione, Katherine S. Tweden, Francine R. Kaufman, Agostino Gnasso, Annamaria Nuzzi, Giuseppe Citro, Luigi Laviola, Sergio Di Molfetta, Dario Pitocco, Elisabetta Lovati, Roberta Assaloni, Antonio Cutruzzolà, Angelo Cignarelli, Barbara Brunato
Publikováno v:
Diabetes, Obesity & Metabolism
Aims This real‐world study evaluated the changes in glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics associated with use of the implantable 180‐day Eversense CGM System (Eversense) in patients with type 1 diabetes. Mat
Publikováno v:
Diabetes Technology & Therapeutics
Previously, the safety and accuracy of the Eversense continuous glucose monitoring (CGM) system were characterized in three pivotal trials among individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) with a single 90- or 180-day sensor inse
Publikováno v:
Diabetes Technology & Therapeutics. 21:677-681
Background: The Eversense® Continuous Glucose Monitoring (CGM) System, with the first 90-day implantable sensor, received FDA (Food and Drug Administration) approval in June 2018. No real-...
Publikováno v:
Expert review of medical devices. 18(10)
Continuous glucose monitoring (CGM) systems offer real-time data to facilitate diabetes management. The novel Eversense CGM has been approved in Europe and the US. The unique characteristics are the fully implantable sensor and the sensor life up to
Autor:
Mark P. Christiansen, Timothy S. Bailey, Anna R Chang, David R. Liljenquist, Katherine S. Tweden, Francine R. Kaufman, Bruce W. Bode, Ronald L. Brazg, Andrew Dehennis, Halis Kaan Akturk, Satish K. Garg, Douglas S Denham
Publikováno v:
Diabetes Technology & Therapeutics
Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implant